Altered Monocyte and Endothelial Cell Adhesion Molecule Expression Is Linked to Vascular Inflammation in Human Immunodeficiency Virus Infection
Authors:
Open Access
- 1 October 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 3 (4) , ofw224
Abstract
Human immunodeficiency virus (HIV)-infected individuals have increased risk for vascular thrombosis, potentially driven by interactions between activated leukocytes and the endothelium. Monocyte subsets (CD14+CD16−, CD14+CD16+, CD14DimCD16+) from HIV negative (HIV−) and antiretroviral therapy-treated HIV positive (HIV+) participants (N = 19 and 49) were analyzed by flow cytometry for adhesion molecule expression (lymphocyte function-associated antigen 1 [LFA-1], macrophage-1 antigen [Mac-1], CD11c/CD18, very late antigen [VLA]-4) and the fractalkine receptor (CX3CR1); these receptors recognize ligands (intercellular adhesion molecules [ICAMs], vascular cell adhesion molecule [VCAM]-1, fractalkine) on activated endothelial cells (ECs) and promote vascular migration. Plasma markers of monocyte (soluble [s]CD14, sCD163) and EC (VCAM-1, ICAM-1,2, fractalkine) activation and systemic (tumor necrosis factor receptor [TNFR-I], TNFR-II) and vascular (lipoprotein-associated phospholipase A2 [Lp-PLA2]) inflammation were measured by enzyme-linked immunosorbent assay. Proportions of CD16+ monocyte subsets were increased in HIV+ participants. Among all monocyte subsets, levels of LFA-1 were increased and CX3CR1 levels were decreased in HIV+ participants (P < .01). Levels of sCD163, sCD14, fractalkine, ICAM-1, VCAM-1, TNFR-II, and Lp-PLA2 were also increased in HIV+ participants (P < .05), and levels of sCD14, TNFR-I, and TNFR-II were directly related to ICAM-1 and VCAM-1 levels in HIV+ participants. Expression of CX3CR1 on monocyte subsets was inversely related to plasma Lp-PLA2 (P < .05 for all). Increased proportions of CD16+ monocytes, cells with altered adhesion molecule expression, combined with elevated levels of their ligands, may promote vascular inflammation in HIV infection.Keywords
Funding Information
- National Institutes of Health (AI-07164, AI-67039, AI-68636, R00HL108743, R56HL126563, R01HL134544))
- AIDS Clinical Trials Group’s Minority Investigator (UM1AI068636)
- Fasenmyer Foundation
- Center for AIDS Research (AI 36219)
- Clinical and Translational Science Collaborative (KL2TR000440)
- National Center for Advancing Translational Sciences
This publication has 49 references indexed in Scilit:
- Soluble Markers of Inflammation and Coagulation but Not T-Cell Activation Predict Non–AIDS-Defining Morbid Events During Suppressive Antiretroviral TreatmentThe Journal of Infectious Diseases, 2014
- Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV InfectionThe Journal of Infectious Diseases, 2014
- Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV InfectionThe Journal of Infectious Diseases, 2011
- Pretreatment Levels of Soluble Cellular Receptors and Interleukin‐6 Are Associated with HIV Disease Progression in Subjects Treated with Highly Active Antiretroviral TherapyThe Journal of Infectious Diseases, 2010
- Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV InfectionPLOS Medicine, 2008
- Major Clinical Outcomes in Antiretroviral Therapy (ART)–Naive Participants and in Those Not Receiving ART at Baseline in the SMART StudyThe Journal of Infectious Diseases, 2008
- High Prevalence of Peripheral Arterial Disease in HIV-Infected PersonsClinical Infectious Diseases, 2008
- Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus DiseaseThe Journal of Clinical Endocrinology & Metabolism, 2007
- Atherosclerosis and HIV in the highly active antiretroviral therapy eraAIDS, 2003
- Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus-positive patientsCoronary Artery Disease, 2000